Copyright
©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Stem Cells. Jul 26, 2014; 6(3): 355-366
Published online Jul 26, 2014. doi: 10.4252/wjsc.v6.i3.355
Published online Jul 26, 2014. doi: 10.4252/wjsc.v6.i3.355
Endothelial progenitor cells in cardiovascular diseases
Poay Sian Sabrina Lee, Kian Keong Poh, Cardiac Department, National University Heart Centre, National University Health System, Singapore and Yong Loo Lin School of Medicine, National University of Singapore, Singapore 119228, Singapore
Author contributions: Lee PSS and Poh KK contributed to this paper.
Supported by The National Medical Research Council, Singapore, No. NMRC/NIG/1038/2010; and the National University Health System Clinician Scientist Program (NCSP) from the Clinician Scientist Unit, Yong Loo Lin School of Medicine, National University of Singapore
Correspondence to: Kian Keong Poh, MBBChir, FRCP, Professor, Cardiac Department, National University Heart Centre, National University Health System, Singapore and Yong Loo Lin School of Medicine, National University of Singapore, 1E Kent Ridge Road, NUHS Tower Block, Level 9, Singapore 119228, Singapore. kian_keong_poh@nuhs.edu.sg
Telephone: +65-92373289 Fax: +65-68722998
Received: November 6, 2013
Revised: March 26, 2014
Accepted: April 3, 2014
Published online: July 26, 2014
Processing time: 255 Days and 4.9 Hours
Revised: March 26, 2014
Accepted: April 3, 2014
Published online: July 26, 2014
Processing time: 255 Days and 4.9 Hours
Core Tip
Core tip: Our review summarizes the important associations between endothelial progenitor cells, cardiovascular risks, drugs and diseases. Current pharmacotherapies may enhance endothelial progenitor cell numbers and function. These and the evolving endothelial progenitor cell-based therapies may be important in the future treatment of cardiovascular diseases.